Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,046 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Completed

Selinexor Treatment of Refractory Myeloma

NCT02336815

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • Mayo Clinic (AZ) Scottsdale, Arizona, United States
  • City of Hope Duarte, California, United States
  • Jonnsson Comprehensive Cancer Center / University of Los Angeles Los Angeles, California, United States
View all 61 locations
View Trial Details
Completed

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

NCT01607892

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Cardiovascular Diseases, +35 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View Trial Details
Completed

Study of bb2121 in Multiple Myeloma

NCT02658929

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • National Cancer Institute Bethesda, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Completed

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

NCT02440464

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Atlanta, Georgia, United States
View all 15 locations
View Trial Details
Completed

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397

Conditions
Adenocarcinoma, Astrocytoma, Blood Protein Disorders, +47 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • UCLA Neuro-Oncology Program Los Angeles, California, United States
  • University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 16 locations
View Trial Details

Related conditions